Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy
dc.contributor.author | Bunchman, Timothy E. | en_US |
dc.contributor.author | Sedman, Aileen B. | en_US |
dc.contributor.author | Kershaw, David B. | en_US |
dc.date.accessioned | 2006-09-11T19:26:52Z | |
dc.date.available | 2006-09-11T19:26:52Z | |
dc.date.issued | 1995-06 | en_US |
dc.identifier.citation | Sedman, Aileen B.; Kershaw, David B.; Bunchman, Timothy E.; (1995). "Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy." Pediatric Nephrology 9(3): 382-385. <http://hdl.handle.net/2027.42/47835> | en_US |
dc.identifier.issn | 0931-041X | en_US |
dc.identifier.issn | 1432-198X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47835 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7632538&dopt=citation | en_US |
dc.description.abstract | Angiotensin converting enzyme (ACE) inhibitors are extensively used for the treatment of hypertension, to decrease proteinuria, and to mitigate hyperfiltration. These drugs now have been shown to be fetotoxic causing profound fetal hypotension, renal tubular dysplasia, anuria-oligohydramnios, growth restriction, hypocalvaria, and death when used in the second and third trimesters of pregnancy. We recommend that ACE inhibitors not be used in pregnancy. However, if a child is born with ACE inhibitor fetopathy, aggressive therapy with dialysis to remove the inhibitor may mitigate the profound hypotensive effects. Therapy will depend on the specific ACE inhibitor, and care recommendations cannot be generalized for the entire class of drugs as their protein binding and volume of distribution differ substantially. | en_US |
dc.format.extent | 421573 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; IPNA | en_US |
dc.subject.other | Therapy | en_US |
dc.subject.other | Pediatrics | en_US |
dc.subject.other | Angiotensin Converting Enzyme Inhibitors | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Fetopathy | en_US |
dc.title | Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Pediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USA | en_US |
dc.contributor.affiliationum | Pediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USA | en_US |
dc.contributor.affiliationum | Pediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 7632538 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47835/1/467_2005_Article_BF02254221.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF02254221 | en_US |
dc.identifier.source | Pediatric Nephrology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.